For DYT1 dystonia, future studies exploring a therapeutic critical period for Tor1a gene replacement will require novel genetic tools for reactivation and/or supplementation of torsinA expression in DYT1 dystonia model systems at different developmental stages. This evidence concerns the gene TOR1A and Dystonia.